CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On January 9, 2017, Celgene Corporation (the “Company”) provided a business update as well as its preliminary 2016 results and financial outlook for 2017 and beyond at the 35th Annual J.P. Morgan Healthcare Conference. Certain preliminary 2016 unaudited results, non-GAAP financial measures and financial outlook are included in the attached press release, which is incorporated herein by reference. The Company will report its 2016 full-year financial results on Thursday, January 26, 2017.
The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished solely to Item 2.02 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information in this Current Report on Form 8-K, including the exhibit attached hereto, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 — Press Release dated January 9, 2017. This exhibit is furnished to Item 2.02 and shall not be deemed to be “filed.”
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information
CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session up +0.54 at 120.18 with shares trading hands.